From Barcelona to Sydney 🦗

Jara Martín Serrano from joins CCI to advance immunotherapy research in neuroblastoma using innovative ex vivo models.

Interested in a secondment? Apply now!
grasshopperconsortium.com

#PediatricOncology #MSCA

Concluí meu mestrado! Tradução e Adaptação da EVAT na oncologia pediátrica do Brasil.Gratidão aos orientadores, IMIP e a equipe do EVAT/St. Jude! Muito feliz e motivada a continuar! 🎗️✨

#OncologiaPediatrica #PediatricOncology #SegurançaDoPaciente #PEWS #EVAT #SUS #Medicina #Pediatria

Learn more about the project that FHS prof Dr. Samantha Pollard is undertaking as one of @terryfoxresearch.bsky.social new investigators!

#SFU #SFUResearch #SFUFHS #PediatricOncology #PrecisionOncology #CancerResearch

Personalised treatment in childhood cancer: A journey through #NTRK fusion testing

📹 Video for patients & families - please share

See full video: cor2ed.com/precision-on...

Supported by an Independent Educational Grant from Bayer

#meded #moleculartesting #pediatriconcology

From Bucharest to Utrecht 🦗

Laura Stefanescu joins the Princess Máxima Center to advance research and training in pediatric leukemia. Her work focuses on therapeutic drug monitoring to improve treatment for children with ALL.

Apply now!
grasshopperconsortium.com

#PediatricOncology #MSCA

Multi-Omics Analysis Reveals New Pathway for Therapy Resistance in Pediatric Medulloblastoma Analyzing paired original and relapsed tumor samples, researchers found genomic differences linked to treatment resistance for medulloblastoma.

Why do some pediatric brain tumors come back after treatment?@cucancercenter.bsky.social researchers and pediatric oncologist Dr. Rajeev Vibhakar identified a new pathway behind therapy resistance that points to future treatment options. #OncSky #PediatricOncology

Read more: https://bit.ly/4u13K6O

The Healing Power of Animal-Assisted Therapy in Pediatric Oncology — HuMOLYTE Discover how therapy dogs are transforming pediatric cancer care by reducing anxiety, easing pain, and bringing comfort to children and families during treatment.

Therapy dogs in pediatric oncology units are helping children cope with pain, fear, and long hospital stays.

#PediatricOncology #AnimalAssistedTherapy #ChildhoodCancer #CancerCare #SupportiveCare

This afternoon at 3:10pm PST #hapc26, Dr. Prasanna Ananth
#YalePediatrics presents during a podium presentation on #endoflife preparation in #pediatriconcology.
@aahpm.bsky.social

🌍 Join the Global Conversation on Pediatric Oncology & Radiology – Tokyo 2026
11th International Congress on Cancer Science and Radiology
📅 July 22–23, 2026
📍 Hilton Tokyo Hotel, Tokyo, Japan
🔗 Learn more: cancertherapy.inovineconferences.com

#cancerscience #radiology #pediatriconcology

Advocates describe multi‑stakeholder platforms — Accelerate and MIB agents — that shape pediatric and osteosarcoma research Advocacy groups and young patient leaders described how multi‑stakeholder platforms (Accelerate) and nonprofit programs (MIB agents) bring patients, clinicians, industry and regulators together to set priorities, run strategy forums, and create mentorship and research funding that influence trial design and policy.

Patient advocates are revolutionizing pediatric and rare cancer research by uniting voices from all corners of the healthcare spectrum to prioritize patient needs and improve trial designs.

Learn more here

#US #PediatricOncology #CitizenPortal #PatientAdvocacy #TrialDesign #ResearchInnovation

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy Research suggests olanzapine may improve control of chemotherapy-induced nausea in children, with 82.3% avoiding vomiting. Is this a game changer for patients? #PediatricOncology #CINV

Research suggests olanzapine may improve control of chemotherapy-induced nausea in children, with 82.3% avoiding vomiting. Is this a game changer for patients? #PediatricOncology #CINV
www.rimpacts.com/rd/p?c=10191... 📄DOI: doi.org/10.4103/abr....

Sustained Benefit of Blinatumomab in Infants With <i>KMT2A</i>-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics KMT2A-rearranged infant ALL (KMT2A-r ALL) has a poor prognosis. Adding blinatumomab, a bispecific T-cell engager targeting CD19, to standard chemotherapy for infants with KMT2A-r ALL improved short-te...

Encouraging data in KMT2A-rearranged infant ALL: in a small cohort (n=30), adding Blinatumomab to Interfant-06 improved 4-yr DFS (83%) and OS (93%) vs historical controls.
Pending validation in larger trials.
#PediatricOncology #Leukemia #Immunotherapy

ascopubs.org/doi/10.1200/...

Best Pediatric Hemato-Oncologist in India – Dr. Manas Kalra

#DrManasKalra #PediatricHematoOncologist #ApolloDelhiIndia #ChildCancerCare #PediatricOncology

🔗 Click to Know More: www.indiacancersurgerysite.com/consult-dr-m...

Addressing Alienation Can Improve Psychosocial Outcomes in Pediatric Cancer - Oncology Nurse Advisor A systematic review explored the types of alienation children and adolescents with cancer experience during their cancer journey.

These findings underscore the need for #caremodels that address #psychosocial disconnection as a core component of #pediatricOncology.

https://bit.ly/4bSe4qW

#PedOnc

Synapse: Your Connection to our MSK Authors
Meet: Armaan Haseeb Siddiquee
Research Focus: SKI Pediatrics; Research Assistant

Antitumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression
synapse.mskcc.org/synapse/work...

#PediatricCancer #PediatricOncology

Every child deserves the best care. That’s why we connect pediatric oncology centers nationwide to share data, research, and expertise. #PediatricOncology

👁️🧬 Can high-dose therapy improve survival in advanced #retinoblastoma? In stage IVa disease, high-dose thiotepa plus autologous stem cell transplantation achieves up to 81% survival, likely due to strong CNS penetration.
Read at doi.org/10.46765/267...
#MedSky #PediatricOncology #Oncology #JBMTCT

🫂 Adequately supported, volunteers can offer unique empathy and authenticity, playing an essential role in #pediatriconcology

A questionnaire to explore nature and correlations of volunteers motivations to evaluate sustainability of engagement.

journals.sagepub.com/share/NBKKKV...

#CanSky

Home - clinicalcanevo.com Menu Home Projects Team Publications Contact The clinical cancer evolution lab We are a team of molecular biologists, biotechnicians, and medical scientists based at the Department of Pediatric Surger...

We have a NEW website for our new team!
Visit us at 👉 clinicalcanevo.com
Learn more about our research, people, and vision — and stay tuned for updates! #CanEvo #CancerResearch #PediatricOncology #TeamScience #TranslationalResearch

Non-malignant features of cancer predisposition syndromes manifesting in childhood and adolescence: a guide for the general pediatrician CPS are genetic disorders that significantly increase the risk of developing malignancies. The malignant features of CPS are well-studied, but recognizing their non-malignant features is crucial for…

The malignant features of CPS are well-studied, but recognizing their non-malignant features is crucial for early diagnosis in children and adolescents.

👉 buff.ly/W5zcQ47

#OncSky #PediatricOncology

Efficacy of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Blinatumomab, a bispecific T-cell engager antibody, has emerged as a promising immunotherapeutic agent for pediatric acute lymphoblastic leukemia (ALL), yet comprehensive evidence regarding its effica...

Blinatumomab (a bispecific T-cell engager) is changing the game for R/R Acute Lymphoblastic Leukemia (ALL). But how much better is it really?

doi.org/10.7759/cureus.86260

#WeiPublications #PediatricOncology #Leukemia #Immunotherapy #MedSky #Pediatrics #Hematology #BiTE #FOAMed

The impact of asparaginase phenotype-related single nucleotide polymorphisms on prognosis in pediatric B-cell precursor acute lymphoblastic leukemia.
Liu, Lixia et al.
Paper
Details
#AcuteLymphoblasticLeukemia #Pharmacogenomics #PediatricOncology

https://c17.ca/committees/CYP-C/Research

The CYP-C database is transforming pediatric cancer research in Canada by connecting data across centers. Better data = better outcomes. Explore: c17.ca/committees/C... #PediatricOncology #CYPC_CCJC

Excited to join the Grasshopper Project at the @themaximacenter.bsky.social! 🚀

I’ll be focusing on genomics, next-generation sequencing, and targeted therapies to help advance precision medicine for children with cancer 🧬.

#MSCA #StaffExchange #PediatricOncology #Genomics #GlobalHealthEquity

My latest essay, Are You Bereaved?, is out in the world. Honored to share my thoughts on a question that I carry with me in @ascocancer.bsky.social JCO’s Art of Oncology.

#narrativemedicine #medsky #writing #grief #PediatricOncology #PalliativeCare #areyoubereaved

ascopubs.org/doi/10.1200/...

At the National Cancer Forum this week, our Ghana team joined partners determined to improve cancer care for children and families. The sense of shared purpose in the room was powerful. 🇬🇭

#CanSky #ChildhoodCancer #PediatricOncology

⚕️ Pediatric cancers are biologically distinct and challenging to model. This review explores how emerging #organoid systems are enabling patient-specific pediatric tumor models, advancing mechanisms and therapy testing in #PediatricOncology.

➡️ doi.org/10.1002/1873-3468.70188

#Grasshopperconsortium #MSCA #StaffExchange #PediatricOncology #ResearchMobility #KnowledgeExchange #HorizonEurope #InnovationInHealth #SkillsDevelopment #Networking

She works clinically in pediatric oncology and within the Bojmar group she studies cancer‑derived extracellular vesicles and the immunological aspect of the pre-metastatic niche.
#PediatricOncology #CancerResearch